Pacad Investment Ltd. increased its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 111.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,300 shares of the pharmaceutical company’s stock after purchasing an additional 4,900 shares during the quarter. Pacad Investment Ltd.’s holdings in GlaxoSmithKline PLC were worth $401,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Bingham Osborn & Scarborough LLC bought a new stake in shares of GlaxoSmithKline PLC in the second quarter worth $311,000. 10 15 Associates Inc. lifted its holdings in GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock valued at $10,022,000 after buying an additional 14,247 shares during the period. Lincluden Management Ltd. lifted its holdings in GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock valued at $5,095,000 after buying an additional 1,990 shares during the period. Anchor Capital Advisors LLC lifted its holdings in GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock valued at $25,858,000 after buying an additional 53,894 shares during the period. Finally, BlueCrest Capital Management Ltd lifted its holdings in GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock valued at $2,157,000 after buying an additional 38,157 shares during the period. 9.28% of the stock is currently owned by institutional investors.
Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 40.58 on Friday. The company’s 50 day moving average is $39.76 and its 200-day moving average is $41.75. The stock has a market capitalization of $99.18 billion, a PE ratio of 40.10 and a beta of 1.03. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.54.
GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a dividend yield of 4.84%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is presently 197.00%.
Several equities analysts recently issued reports on GSK shares. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $44.67.
GlaxoSmithKline PLC Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with our FREE daily email newsletter.